Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLBE | ISIN: SE0012675361 | Ticker-Symbol: 6IRA
Frankfurt
29.08.25 | 08:14
0,243 Euro
+0,83 % +0,002
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IRLAB THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
IRLAB THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur IRLAB THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrChange in Number of Shares and Votes in IRLAB Therapeutics AB197GOTHENBURG, SE / ACCESS Newswire / August 29, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - During August 2025, the registered number of shares and votes in IRLAB Therapeutics AB ("IRLAB") has...
► Artikel lesen
MiIRLAB Therapeutics: IRLAB Publishes Interim Report for the Period January - June 2025235GOTHENBURG, SE / ACCESS Newswire / August 27, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced...
► Artikel lesen
22.08.IRLAB Therapeutics: IRLAB: Invitation to The Interim Report for Q2 2025 Presentation and Webcast212GOTHENBURG, SE / ACCESS Newswire / August 22, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced...
► Artikel lesen
21.08.IRLAB Therapeutics: IRLAB Appoints Roy Jonebrant as Interim CFO213GOTHENBURG, SE / ACCESS Newswire / August 21, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced...
► Artikel lesen
11.08.IRLAB Therapeutics: IRLAB's CFO Viktor Siewertz Leaves the Company for a New Leading Position319GOTHENBURG, SE / ACCESS Newswire / August 11, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announces...
► Artikel lesen
IRLAB THERAPEUTICS Aktie jetzt für 0€ handeln
30.06.XFRA CAPITAL ADJUSTMENT INFORMATION - 30.06.20251.708Das Instrument EMH DE000A2YN777 PFERDEWETTEN.DE AG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 30.06.2025 und ex Kapitalmassnahme am 01.07.2025 The instrument EMH DE000A2YN777 PFERDEWETTEN.DE...
► Artikel lesen
24.06.IRLAB Therapeutics AB: The Board of Directors of IRLAB has resolved on an 85 per cent secured rights issue of approximately SEK 136 million and receives extended debt financing of SEK 30 million177THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE...
► Artikel lesen
11.06.Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB349GOTHENBURG, SWEDEN / ACCESS Newswire / June 11, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Today, on Wednesday June 11, 2025, IRLAB Therapeutics AB held its Annual General Meeting.The following...
► Artikel lesen
04.06.IRLAB Therapeutics: IRLAB Participates in Aktiespararna's Event - Aktiedagarna295GOTHENBURG, SE / ACCESS Newswire / June 4, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, June 4, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
28.05.IRLAB Therapeutics: IRLAB Reports Positive Results from the Second Part of a Phase I Study with IRL757641GOTHENBURG, SE / ACCESS Newswire / May 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers...
► Artikel lesen
15.05.IRLAB Therapeutics: IRLAB to Present at BioStock Global Forum 2025328GOTHENBURG, SE / ACCESS Newswire / May 15, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 15, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers...
► Artikel lesen
13.05.IRLAB Therapeutics: IRLAB is Granted a Patent Expanding the Patent Protection for the Drug Candidate Mesdopetam in the US345GOTHENBURG, SE / ACCESS Newswire / May 13, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 13, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
12.05.Notice to the Annual General Meeting in IRLAB Therapeutics AB278GOTHENBURG, SE / ACCESS Newswire / May 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB, reg. no. 556931-4692 ("IRLAB" or the "Company"), holds its Annual General Meeting...
► Artikel lesen
07.05.IRLAB Therapeutics: IRLAB Publishes Interim Report for the Period January - March 2025363GOTHENBURG, SE / ACCESS Newswire / May 7, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that...
► Artikel lesen
06.05.IRLAB Therapeutics: IRLAB: Invitation to the Interim Report for Q1 2025 Presentation and Webcast355GOTHENBURG, SE / ACCESS Newswire / May 6, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 6, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
25.04.IRLAB Therapeutics: IRLAB publishes the Annual Report for 2024423GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 25, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company...
► Artikel lesen
07.04.IRLAB Therapeutics: IRLAB Presents at Two Redeye Events419GOTHENBURG, SE / ACCESS Newswire / April 7, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announces that...
► Artikel lesen
01.04.IRLAB Therapeutics: IRLAB to Present Clinical and Preclinical Data at the AD/PD 2025: 19th International Conference on Alzheimer's & Parkinson's Diseases371GOTHENBURG, SE / ACCESS Newswire / April 1, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 1, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
28.03.IRLAB Therapeutics: IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease834GOTHENBURG, SE / ACCESS Newswire / March 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, March 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that...
► Artikel lesen
27.03.IRLAB Therapeutics - Next steps laid out for IRL757418IRLAB has confirmed that clinical candidate IRL757, which has been designed to address apathy in patients with neurodegenerative conditions, will proceed to the next stages of clinical development....
► Artikel lesen
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1